GlassScriptPhysician profile
Christine E Kennedy
NPI 1114926581
$2,286.36
in general payments reported to CMS, 2019-2025
13 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.99 · 2022: $244 · 2023: $619 · 2024: $1,001 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,047.81 | 2022-2025 | Injectafer, Enhertu, Vanflyta |
| Incyte Corporation | $339.83 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $211.64 | 2024-2025 | |
| Astellas Pharma US INC | $174.54 | 2021-2025 | Xtandi, Padcev |
| Abbvie INC. | $118.79 | 2022-2025 | |
| Eisai INC. | $94.32 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $90.52 | 2023-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $56.43 | 2024 | Imfinzi |
| Genentech USA, INC. | $46.41 | 2023-2024 | Venclexta |
| Seagen INC. | $41.55 | 2023 | Padcev |
| Pfizer INC. | $31.44 | 2024-2025 | |
| Medline Industries LP | $19.32 | 2025 | |
| Coherus Oncology, INC. | $13.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.